Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report.

Shawnalyn W SunagawaJoshua P HavensAnthony T PodanyBryan WalkerKimberly K ScarsiSara H Bares

Published in: Open forum infectious diseases (2023)

As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC 90 .

Keyphrases

hiv infected patients
antiretroviral therapy
hiv infected
human immunodeficiency virus
high dose
hiv positive
hiv aids
low dose
emergency department
protein protein
human health
drug induced
small molecule
climate change
community dwelling
men who have sex with men
electronic health record